Theriva Biologics, Inc. (SFY0)

Overview

Theriva Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic solutions for diseases with significant unmet medical needs. With its roots as Synthetic Biologics, Inc., the company underwent a rebranding to Theriva Biologics Inc. in October 2022, emphasizing its evolved focus towards pioneering biological treatments. Its headquarters are located in Rockville, Maryland, where it spearheads innovative research and development efforts. The company is notable for its collaborations with esteemed institutions such as Intrexon Corporation, The University of Texas at Austin, Cedars-Sinai Medical Center, and a clinical trial agreement with Washington University School of Medicine in St. Louis. These partnerships facilitate the advancement of Theriva's leading-edge portfolio, particularly in conducting key clinical trials.

Products and Services

Theriva Biologics Inc. boasts a diverse pipeline of product candidates aimed at addressing a wide range of critical healthcare challenges:

• SYN-004: A pioneering product designed to degrade various commonly used intravenous beta-lactam antibiotics in the GI tract. This is primarily for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients.
• SYN-020: A recombinant oral formulation of the enzyme intestinal alkaline phosphatase, developed to treat both local GI and systemic diseases. This enzyme plays a crucial role in maintaining gut health and systemic physiological balance.
• VCN-01: Focused on the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma, VCN-01 represents Theriva's foray into oncology, aiming to offer new hope for cancer patients through cutting-edge therapeutic options.
• SYN-006: Aimed at preventing aGVHD and infections by carbapenem-resistant enterococci, SYN-006 is in development to provide a solution to the growing issue of resistance in the healthcare setting.
• SYN-007: This candidate is developed for preventing antibiotic-associated diarrhea associated with oral ß-lactam antibiotics, representing an important step towards mitigating the side effects of antibiotic treatments.
• SYN-005: Targeted at the prevention and treatment of pertussis, SYN-005 is part of Theriva’s portfolio addressing infectious diseases, aiming to enhance public health protection against highly contagious diseases.
• VCN-11: Another oncology product candidate, VCN-11 is under development to treat various forms of cancer, showcasing Theriva Biologics’ commitment to expanding its cancer treatment portfolio.